The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia
Official Title: A Phase I Dose Escalation Study of VS-4718, A Focal Adhesion Kinase Inhibitor, In Subjects With Relapsed or Refractory Acute Myeloid Leukemia or B-Cell Acute Lymphoblastic Leukemia
Study ID: NCT02215629
Brief Summary: The main purpose of this study is to test the safety and efficacy of VS-4718 in two types of leukemia patients and to find the right dose of VS-4718 for future clinical trials. Other purposes of this study include: * Testing for study drug VS-4718 levels in blood over time and what happens to the study drug in patients. * To find out if there are certain biomarkers in leukemia patients that predict if and how 4718 study drug may or may not work.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Name: Hagop Youssoufian, MD
Affiliation: Verastem, Inc.
Role: STUDY_CHAIR